新闻源 财富源

2019年10月20日 星期天

誉衡药业(002437)公告正文

誉衡药业:2015年第三季度报告全文

公告日期:2015-10-27

  哈尔滨誉衡药业股份有限公司                            2015 年第三季度报告全文




证券代码:002437                  证券简称:誉衡药业   公告编号:2015-134




                         哈尔滨誉衡药业股份有限公司

                               2015 年第三季度报告




                                  2015 年 10 月




                                       第1页
   哈尔滨誉衡药业股份有限公司                                           2015 年第三季度报告全文




                                  第一节 重要提示

    公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整,不存在虚
假记载、误导性陈述或者重大遗漏,并承担个别和连带的法律责任。
    所有董事均已出席了审议本次季报的董事会会议。
    公司负责人朱吉满、主管会计工作负责人刁秀强及会计机构负责人(会计主管人员)程朝阳声明:保证
季度报告中财务报表的真实、准确、完整。




                                           第2页
       哈尔滨誉衡药业股份有限公司                                                                  2015 年第三季度报告全文




                               第二节 主要财务数据及股东变化

一、主要会计数据和财务指标

公司是否因会计政策变更及会计差错更正等追溯调整或重述以前年度会计数据
□ 是 √ 否

                                         本报告期末                        上年度末             本报告期末比上年度末增减

总资产(元)                                   8,023,375,809.26              4,922,349,658.56                       63.00%

归属于上市公司股东的净资产(元)               3,447,109,025.57              3,021,221,243.02                       14.10%

                                                          本报告期比上年同期                             年初至报告期末比上
                                       本报告期                                   年初至报告期末
                                                                  增减                                       年同期增减

营业收入(元)                         662,947,486.01                    42.49%       1,927,552,868.07              40.51%

归属于上市公司股东的净利润(元)       175,382,136.73                    83.61%        499,076,807.55               67.37%

归属于上市公司股东的扣除非经常
                                       159,262,392.28                   101.67%        469,931,537.35               74.33%
性损益的净利润(元)

经营活动产生的现金流量净额(元)          --                       --                  600,024,249.54               70.50%

基本每股收益(元/股)                              0.24                  71.43%                   0.68              58.14%

稀释每股收益(元/股)                              0.24                  71.43%                   0.68              58.14%

加权平均净资产收益率                             5.22%                   1.57%                  15.45%               3.65%



截止披露前一交易日的公司总股本:

截止披露前一交易日的公司总股本(股)                                                                             731,890,250

公司报告期末至季度报告披露日股本是否因发行新股、增发、配股、股权激励行权、回购等原因发生变化且影响所有者权益
金额
□是    √否
非经常性损益项目和金额
√ 适用 □ 不适用
                                                                                                                    单位:元

                            项目                              年初至报告期期末金额                        说明

非流动资产处置损益(包括已计提资产减值准备的冲销部分)                      449,913.09

                                                                                          其中,黑龙江省企业流动资金贷款
                                                                                          贴息 200 万元,哈尔滨市企业流动
计入当期损益的政府补助(与企业业务密切相关,按照国家统                                    资金贷款贴息 800 万元,拉萨市曲
                                                                          27,307,746.22
一标准定额或定量享受的政府补助除外)                                                      水县政府企业发展基金 507.10 万
                                                                                          元,南京河西中央商务区企业扶持
                                                                                          资金 302.40 万元,上海市高新技术


                                                          第3页
     哈尔滨誉衡药业股份有限公司                                                               2015 年第三季度报告全文

                                                                                     成果转化财政扶持资金 302.50 万
                                                                                     元。

除同公司正常经营业务相关的有效套期保值业务外,持有交易
性金融资产、交易性金融负债产生的公允价值变动损益,以及
                                                                     4,308,408.42 银行理财产品收益。
处置交易性金融资产、交易性金融负债和可供出售金融资产取
得的投资收益

                                                                                     2014 年 12 月 26 日,公司下属公司
                                                                                     南京万川华拓医药有限公司(以下
                                                                                     简称“南京万川”)与石药集团远大
除上述各项之外的其他营业外收入和支出                                 3,344,792.93
                                                                                     (大连)制药有限公司达成《执行
                                                                                     和解协议》。南京万川取得营业外收
                                                                                     入 342.57 万元。

减:所得税影响额                                                     5,965,289.00

     少数股东权益影响额(税后)                                         300,301.46

合计                                                                29,145,270.20                     --

对公司根据《公开发行证券的公司信息披露解释性公告第 1 号——非经常性损益》定义界定的非经常性损益项目,以及把《公
开发行证券的公司信息披露解释性公告第 1 号——非经常性损益》中列举的非经常性损益项目界定为经常性损益的项目,应
说明原因
□ 适用 √ 不适用
公司报告期不存在将根据《公开发行证券的公司信息披露解释性公告第 1 号——非经常性损益》定义、列举的非经常性损益
项目界定为经常性损益的项目的情形。


二、报告期末股东总数及前十名股东持股情况表

1、报告期末普通股股东总数及前十名普通股股东持股情况表

                                                                                                              单位:股

报告期末普通股股东总数                                                                                         27,819

                                           前 10 名普通股股东持股情况

                                                                               持有有限售条        质押或冻结情况
               股东名称                 股东性质      持股比例    持股数量
                                                                               件的股份数量 股份状态         数量

哈尔滨恒世达昌科技有限公司           境内非国有法人      42.68% 312,375,000                  0 质押        240,190,000

YU HENG INTERNATIONAL
                                     境外法人            19.56% 143,192,968                  0
INVESTMENTS CORPORATION

ORIENTAL KEYSTONE INVESTMENT
                                     境外法人             1.95%   14,301,533                 0
LIMITED

中融国际信托有限公司-中融-日进斗
金 1 号结构化证券投资集合资金信托计 其他                  1.37%   10,017,370                 0


杨红冰                               境内自然人           0.89%    6,535,000         6,535,000


                                                      第4页
    哈尔滨誉衡药业股份有限公司                                                             2015 年第三季度报告全文

尹美娟                                境内自然人         0.82%     5,988,582              0

招商银行股份有限公司-汇添富医疗服
                                      其他               0.82%     5,976,337              0
务灵活配置混合型证券投资基金

中国农业银行股份有限公司-宝盈转型
                                      其他               0.77%     5,610,416              0
动力灵活配置混合型证券投资基金

中央汇金投资有限责任公司              国有法人           0.72%     5,255,900              0

天安财产保险股份有限公司-保赢 1 号 其他                 0.55%     4,047,633              0

                                      前 10 名无限售条件普通股股东持股情况

                                                                 持有无限售条件               股份种类
                           股东名称
                                                                 普通股股份数量      股份种类            数量

哈尔滨恒世达昌科技有限公司                                            312,375,000 人民币普通股           312,375,000

YU HENG INTERNATIONAL INVESTMENTS CORPORATION                         143,192,968 人民币普通股           143,192,968

ORIENTAL KEYSTONE INVESTMENT LIMITED                                   14,301,533 人民币普通股            14,301,533

中融国际信托有限公司-中融-日进斗金 1 号结构化证券投资集合
                                                                       10,017,370 人民币普通股            10,017,370
资金信托计划

尹美娟                                                                  5,988,582 人民币普通股             5,988,582

招商银行股份有限公司-汇添富医疗服务灵活配置混合型证券投资
                                                                        5,976,337 人民币普通股             5,976,337
基金

中国农业银行股份有限公司-宝盈转型动力灵活配置混合型证券投
                                                                        5,610,416 人民币普通股             5,610,416
资基金

中央汇金投资有限责任公司                                                5,255,900 人民币普通股             5,255,900

天安财产保险股份有限公司-保赢 1 号                                     4,047,633 人民币普通股             4,047,633

尹江                                                                    3,182,930 人民币普通股             3,182,930

                                                                 哈尔滨恒世达昌科技有限公司(以下简称“恒世达
                                                                 昌”)、YU HENG INTERNATIONAL INVESTMENTS
                                                                 CORPORATION 以及 ORIENTAL KEYSTONE
                                                                 INVESTMENT LIMITED 由同一实际控制人朱吉满控
上述股东关联关系或一致行动的说明                                 制。未知其他股东是否存在关联关系,也未知是否属
                                                                 于《上市公司收购管理办法》中规定的一致行动人。
                                                                 实际控制人朱吉满通过《中融国际信托有限公司-中
                                                                 融-日进斗金 1 号结构化证券投资集合资金信托计
                                                                 划》持有公司 10,017,370 股股票。

                                                                 前 10 名普通股股东中,尹美娟通过参与融资融券业
前 10 名普通股股东参与融资融券业务股东情况说明(如有)
                                                                 务持有公司股票 5,761,882 股。

公司前 10 名普通股股东、前 10 名无限售条件普通股股东在报告期内是否进行约定购回交易
□ 是 √ 否
公司前 10 名普通股股东、前 10 名无限售条件普通股股东在报告期内未进行约定购回交易。




                                                     第5页
    哈尔滨誉衡药业股份有限公司                                                                     2015 年第三季度报告全文




                                            第三节 重要事项

一、报告期主要会计报表项目、财务指标发生变动的情况及原因

√ 适用 □ 不适用
1、2015年9月30日资产负债表项目

项目                     期末余额               期初余额            变动率       原因说明
应收票据                      21,644,680.94         12,303,063.91      75.93% 主要系本期票据结算业务增加
                                                                                 主要系本期新增山西普德药业股份有限公司(以
预付账款                     201,580,758.79        114,570,665.13      75.94%
                                                                                 下简称“普德药业”)以及预付货款业务增加
应收利息                            15,774.00         471,828.56      -96.66% 主要系本期利息已经收回
其他应收款                    80,884,257.96         53,634,666.41      50.81% 主要系本期代理保证金、押金等增加
存货                         258,463,970.87        163,445,036.83      58.14% 主要系本期合并报表增加了普德药业
一年内到期的非流动资产           6,548,494.34        1,340,962.52     388.34% 主要系本期合并报表增加了普德药业
其他流动资产                  33,735,605.25          9,276,704.89     263.66% 主要系本期银行理财产品的增加
                                                                                 系本期增加了对非营利性医院射阳振阳医院的投
可供出售金融资产              50,832,196.80         11,300,796.80     349.81%
                                                                                 资及海外投资基金毓承资本的投资
                                                                                 系本期增加了对杭州药享售投资管理有限公司
长期股权投资                     3,000,000.00                0.00            -
                                                                                 30%股权投资

固定资产                    1,491,451,035.04       811,046,254.34      83.89% 主要系本期合并报表增加了普德药业

在建工程                     205,756,352.31         20,354,834.70     910.85% 主要系本期合并报表增加了普德药业

                                                                                 系本期增加对山东誉衡药业有限公司银杏树种植
生产性生物资产                      82,450.00                0.00            -
                                                                                 基地的投入
                                                                                 主要系本期增加对鲁比前列酮、布洛芬注射液的
开发支出                      47,330,014.00         33,504,799.88      41.26%
                                                                                 研发投入
商誉                        3,638,786,092.29 1,848,291,450.02          96.87% 主要系本期并购普德药业形成
递延所得税资产                17,129,837.06         12,071,398.83      41.90% 主要系本期合并报表增加了普德药业
                                                                                 主要系与购建固定资产、无形资产、长期股权投
其他非流动资产               428,721,439.64        274,798,597.08      56.01%
                                                                                 资相关的预付款、保证金等
短期借款                    1,800,000,000.00       780,000,000.00     130.77% 主要系收购项目导致银行借款增加
                                                                                 主要系本期新增普德药业,以及应付材料款、设
应付账款                     138,778,982.72         66,950,608.77     107.29%
                                                                                 备款的增加
应付票据                     150,095,186.21          9,940,106.00 1410.00% 主要系本期票据支付业务增加
应付利息                         2,740,472.23        1,469,808.13      86.45% 主要系本期应支付的借款利息增加
                                                                                 系应支付股权激励计划中持有限制性股票的股东
应付股利                         3,189,025.00                0.00            -
                                                                                 的现金分红款
一年内到期的非流动负债      1,229,188,363.17       170,992,020.55     618.86% 系一年内需要支付的股权收购款增加
其他流动负债                  49,000,000.00                  0.00            - 系上海华拓医药科技发展有限公司(以下简称“上



                                                           第6页
    哈尔滨誉衡药业股份有限公司                                                                          2015 年第三季度报告全文

                                                                                 海华拓”)银行贷款融资业务形成
长期应付款                      456,546,984.65      336,702,647.81      35.59% 系一年以上需要支付的股权收购款增加
专项应付款                        2,158,700.49                0.00             - 系普德药业的专项应付款
递延收益                         46,287,062.07       15,775,858.38    193.40% 主要系本期合并范围新增了普德药业
递延所得税负债                   34,029,031.35       10,764,610.53    216.12% 系本期并购评估增值对应的递延所得税增加所致
少数股东权益                    237,968,818.67       80,969,088.79    193.90% 主要系增加了普德药业少数股东权益
2、2015年1-9月利润表项目
           项目                本期发生额          上期发生额         变动率                           原因说明
                                                                                 主要系本期较上年同期增加普德药业以及注射用
营业收入                      1,927,552,868.07 1,371,851,676.94         40.51% 磷酸肌酸纳、葡萄糖酸锌钙口服液、安脑丸(片)
                                                                                 业务增长
                                                                                 主要系本期较上年同期增加普德药业以及注射用
营业成本                        699,588,980.68      515,173,340.16      35.80% 磷酸肌酸纳、葡萄糖酸锌钙口服液、安脑丸(片)
                                                                                 业务增长
                                                                                 主要系本期较上年同期增加普德药业以及注射用
营业税金及附加                   25,951,004.42       17,740,197.85      46.28% 磷酸肌酸纳、葡萄糖酸锌钙口服液、安脑丸(片)
                                                                                 业务增长
                                                                                 主要系本期新增普德药业以及公司研发费用、人
管理费用                        292,604,197.69      178,611,331.10      63.82%
                                                                                 力资源费用、折旧摊销费用等增长
财务费用                         60,156,286.25       16,803,880.99    257.99% 主要系借款增加导致利息支出增加
资产减值损失                        897,775.97         515,923.72       74.01% 主要系本期应收款项增加
营业外支出                          424,565.39        3,816,309.72     -88.87% 主要系上年同期发生捐赠支出
所得税费用                      101,075,260.71       62,399,942.09      61.98% 主要系本期合并范围增加、利润增加
3、2015年1-9月现金流量表项目
           项目                本期发生额          上期发生额         变动率                           原因说明
                                                                                 主要系本期较上年同期增加普德药业以及注射用
经营活动产生的现金流量
                                600,024,249.54      351,920,948.83      70.50% 磷酸肌酸纳、葡萄糖酸锌钙口服液、安脑丸(片)
净额
                                                                                 业务增长
投资活动产生的现金流量
                              -1,619,407,817.26 -1,257,933,092.62      -28.74% 主要系本期收购项目支付的现金增加
净额
筹资活动产生的现金流量
                                860,739,882.30      425,140,425.99    102.46% 主要系本期银行借款的增加
净额


二、重要事项进展情况及其影响和解决方案的分析说明

√ 适用 □ 不适用
1、已发布临时公告且无进展的重要事项

               重要事项概述                      披露日期                           临时报告披露网站查询索引

                                                                详 见 发 布 在 《 中 国 证 券 报 》、《 证 券 时 报 》 及 巨 潮 资 讯 网
终止非公开发行股票                       2015 年 09 月 10 日 www.cninfo.com.cn(以下简称:“指定披露媒体”)的 2015-114
                                                                号公告《关于终止 2015 年度非公开发行股票方案的公告》。



                                                            第7页
   哈尔滨誉衡药业股份有限公司                                                                     2015 年第三季度报告全文

                                                                 详见发布在指定披露媒体的 2015-117 号公告《关于对深圳证券
                                           2015 年 09 月 18 日
                                                                 交易所监管关注函回复的公告》。

                                                                 详见发布在指定披露媒体的 2015-121 号公告《关于收到<中国
                                           2015 年 09 月 24 日
                                                                 证监会行政许可申请终止审查通知书>的公告》。

公司控股子公司哈尔滨蒲公英药业有限
公司获得新版 GMP 证书,认证范围:片                              详见发布在指定披露媒体的 2015-089 号公告《关于控股子公司
                                           2015 年 07 月 10 日
剂(仅限安脑片)、丸剂(蜜丸)(含中药                           获得新版 GMP 证书的公告》。
材前处理)

公司全资子公司誉衡金融服务(深圳)有                             详见发布在指定披露媒体的 2015-091 号公告《关于全资子公司
                                           2015 年 07 月 14 日
限公司(以下简称“誉衡金服”)出资 5,000                         誉衡金融服务(深圳)有限公司投资设立商业保理公司的公告》。
万元人民币设立誉衡商业保理(深圳)有
                                                           详见发布在指定披露媒体的 2015-099 号公告《关于誉衡商业保
限公司(以下简称“誉衡保理”),并完成 2015 年 08 月 11 日
                                                           理(深圳)有限公司完成工商登记的公告》。
工商登记

终止收购维康医药集团有限公司及其下                               详见发布在指定披露媒体的 2015-092 号公告《关于拟筹划收购
属沈阳维康医院(有限公司)、沈阳沈北                             维康医药集团有限公司及其下属沈阳维康医院(有限公司)、沈
                                           2015 年 07 月 14 日
维康医院和沈阳维康医院全部或部分股                               阳沈北维康医院和沈阳维康医院全部或部分股权或权益事宜进
权或权益                                                         展的公告》。

公司出资 1,000 万美元参股设立海外投资                            详见发布在指定披露媒体的 2015-095 号公告《关于拟参股设立
                                           2015 年 07 月 17 日
基金合伙企业                                                     海外投资基金合伙企业的公告》。

公司拟以现金增资形式取得射阳振阳医                               详见发布在指定披露媒体的 2015-102 号公告《关于以现金增资
                                           2015 年 08 月 18 日
院 70%权益                                                       形式取得射阳振阳医院 70%权益的公告》。

                                                                 详见发布在指定披露媒体的 2015-103 号公告《关于设立誉衡(深
                                           2015 年 08 月 18 日
公司出资 10,000 万人民币设立深圳誉衡                             圳)投资有限公司的公告》。
投资有限公司,并完成工商变更登记                                 详见发布在指定披露媒体的 2015-116 号公告《关于全资子公司
                                           2015 年 09 月 16 日
                                                                 深圳誉衡投资有限公司完成工商登记的公告》。

                                                         详见发布在指定披露媒体的 2015-107 号公告《关于为控股子公
公司对控股子公司及下属公司进行担保: 2015 年 08 月 26 日 司山西普德药业股份有限公司申请银行综合授信提供担保的公
1、为山西普德药业股份有限公司申请银                      告》。
行综合授信 2.5 亿元提供为期一年的连带
                                                                 详见发布在指定披露媒体的 2015-108 号公告《关于为下属公司
责任保证担保;2、为哈尔滨莱博通药业
                                           2015 年 08 月 26 日 哈尔滨莱博通药业有限公司申请银行综合授信提供担保的公
有限公司申请银行综合授信 2 亿元提供为
                                                                 告》。
期一年的连带责任保证担保;3、为上海
华拓申请银行综合授信 1.5 亿元提供为期                            详见发布在指定披露媒体的 2015-115 号公告《关于为控股子公

一年的连带责任保证担保                     2015 年 09 月 10 日 司上海华拓医药科技发展有限公司申请银行综合授信提供担保
                                                                 的公告》。

公司拟以人民币 2,271.75 万元收购郁春辉                           详见发布在指定披露媒体的 2015-109 号公告《关于收购上海华
                                           2015 年 08 月 26 日
持有的上海华拓 1.14%股权                                         拓医药科技发展有限公司 1.14%股权的公告》。

拟以 350 万元人民币参股上海潜龙誉瀚投
资管理有限公司(以下简称“潜龙誉瀚”),                    详见发布在指定披露媒体的 2015-110 号公告《关于拟设立上海
                                        2015 年 08 月 26 日
同时,拟以有限合伙人身份投资 2 亿元人                       誉瀚股权投资基金合伙企业(有限合伙)的公告》。
民币参与由潜龙誉瀚发起设立的上海誉



                                                           第8页
    哈尔滨誉衡药业股份有限公司                                                                         2015 年第三季度报告全文

瀚股权投资基金合伙企业(有限合伙)

公司拟以人民币 6,500 万元收购澳诺(青                                详见发布在指定披露媒体的 2015-111 号公告《关于拟收购澳诺
                                               2015 年 08 月 26 日
岛)制药有限公司 100%股权                                            (青岛)制药有限公司 100%股权的公告》。

与 波 兰 Bioton S.A. 及 其 新 加 坡 子 公 司                         详见发布在指定披露媒体的 2015-122 号公告《关于与波兰
SciGen Limited 签订《重组人胰岛素产品 2015 年 09 月 24 日 Bioton S.A.及其新加坡子公司 SciGen Limited 签订<重组人胰岛
供应与分销协议》                                                     素产品供应与分销协议>的公告》。

公司互联网金融服务平台“誉金所”正式                                 详见发布在指定披露媒体的 2015-123 号公告《关于公司互联网
                                               2015 年 09 月 26 日
上线运营                                                             金融服务平台“誉金所”正式上线运营的公告》。

                                                                     详见发布在指定披露媒体的 2015-125 号公告《关于获批设立博
公司获批设立博士后科研工作站                   2015 年 10 月 08 日
                                                                     士后科研工作站的公告》。

2、报告期内发生的其他重要事项
⑴ 誉衡金融服务板块初步形成
    根据公司对誉衡金服的定位,誉衡金服作为公司拓展金融板块的投资管理旗舰平台,将拓展包括互联网金融、基金、商
业保理、融资租赁、小额贷款、第三方支付平台等领域的业务。(详见2015年6月16日发布在指定媒体的2015-078号公告《关
于设立全资子公司誉衡前海金融服务(深圳)有限公司的公告》)
    报告期内,全资子公司誉衡金服先后新设成立下属公司誉衡基石(深圳)基金管理有限公司、誉衡保理,持股比例均为
100%,注册资金分别为3,000万元、5,000万元。此外,为理顺金融板块的业务关系,公司将誉金所(深圳)互联网金融服务
有限公司100%股权转让至全资子公司誉衡金服旗下。
    截至报告期末,誉衡金服下设的互联网金融、基金、商业保理平台搭建完毕。
⑵ 公司际控制人朱吉满先生增持公司股份
    报告期内,公司实际控制人朱吉满先生通过信托计划间接增持公司股票9,479,878股,占公司总股本的1.30%。(详见2015
年9月22日发布在指定披露媒体的2015-119号公告《关于实际控制人朱吉满先生增持公司股票的公告》)。
    2015年9月21日,朱吉满先生通过“中融国际信托有限公司《中融-日进斗金1号结构化证券投资集合资金信托计划》”
继续增持公司股份1,446,920股,占公司总股本的0.20%。
    截止报告期末,朱吉满先生通过信托计划累计增持公司股票10,926,798股,占公司总股本的1.49%。
⑶ 公司以账面净资产出售吉林省靶向生物医药科技有限公司(以下简称“靶向生物”)100%股权
    报告期内,公司将全资子公司靶向生物100%股权以账面净资产2.49万元对外出售,并完成工商变更登记,截至报告期末,
靶向生物已不是公司全资子公司。
⑷ 鹿瓜多肽注射液被写入《临床路径治疗药物释义》骨科分册
    公司主要产品之一鹿瓜多肽注射液,被写入由协和医院、积水潭医院、北京大学第三医院、北京大学人民医院等多家医
院编审专家编制而成的《临床路径治疗药物释义》骨科分册。该释义作为医疗机构开展临床路径管理的指导用书,对鹿瓜多
肽在缩短骨折愈合时间、提高骨折愈合质量、减轻软骨破坏、抑制炎症、消肿止痛等方面给予了肯定与推荐。
⑸ 荣获多项荣誉
    报告期内,公司入选《2015福布斯亚洲中小上市企业200强》;
    在证券时报、中国基金报、中国上市公司发展联盟、新财富杂志社联合主办的“中国上市公司价值评选”高峰论坛上,
公司被评选为“中国中小板最具成长性上市公司十强”和“中国中小板上市公司价值五十强”;
    公司入选中国医药企业管理协会评选的“第七届中国最具竞争力医药上市公司20强”,位列第10位。


三、公司或持股 5%以上股东在报告期内发生或以前期间发生但持续到报告期内的承诺事项

√ 适用 □ 不适用

     承诺事由           承诺方                                       承诺内容                              承诺   承诺 履行



                                                               第9页
   哈尔滨誉衡药业股份有限公司                                                            2015 年第三季度报告全文

                                                                                              时间    期限 情况

                              承诺如果公司 2005 年度、2006 年度按照高新技术企业税收优惠政策
                                                                                              2010
                   恒世达昌; 所享受的按 15%的税率征收企业所得税的税收优惠被认定无效,本公                     正常
                                                                                              年 06
                   朱吉满;   司需要补缴税金、滞纳金、罚金或承担其它赔偿责任的,将由恒世达            长期     履行
                                                                                              月 23
                   白莉惠     昌以及朱吉满和白莉惠夫妇向本公司予以全额补偿,并承担连带责                       中
                                                                                              日
                              任。

                              承诺其持有权益达 50%以上或实际控制的企业或单位(“附属公司”)
                              目前并没有直接或间接地从事任何与公司实际从事的业务发生利益
                              冲突或在市场、资源、地域方面存在竞争的任何业务活动。其及其附 2010
                                                                                                               正常
                              属公司在今后的任何时间不会直接或间接地以任何方式(包括但不限 年 06
                   恒世达昌                                                                           长期     履行
                              于自营、合资或联营)参与或进行与公司实际从事的业务存在直接或 月 23
                                                                                                               中
                              间接竞争的任何业务活动(与公司合作开发除外)。凡其及其附属公司 日
                              有任何商业机会可从事、参与或入股任何可能会与公司生产经营构成
首次公开发行或再              竞争的业务,会将上述商业机会优先让予公司。
融资时所作承诺
                              承诺其及其实际控制的企业或单位(“附属公司”)目前并没有直接或
                              间接地从事任何与公司实际从事的业务发生利益冲突或在市场、资
                              源、地域方面存在竞争的任何业务活动。其及其附属公司在今后的任 2010
                                                                                                               正常
                   朱吉满;   何时间不会直接或间接地以任何方式(包括但不限于自营、合资或联 年 06
                                                                                                      长期     履行
                   白莉惠     营)参与或进行与公司实际从事的业务存在直接或间接竞争的任何业 月 23
                                                                                                               中
                              务活动(与公司合作开发除外)。其及其附属公司有任何商业机会可从 日
                              事、参与或入股任何可能会与公司生产经营构成竞争的业务,会将上
                              述商业机会优先让予公司。

                   朱吉满、                                                                   2010
                              限售期届满后,在担任公司董事、监事或高管人员期间,每年转让的                     正常
                   白莉惠、                                                                   年 06
                              股份不超过所间接持有公司股份总数的 25%;离职后半年内,不转让            长期     履行
                   王东绪、                                                                   月 23
                              所间接持有的公司股份。                                                           中
                   杨红冰                                                                     日

                                                                                              2014
                                                                                                               正常
其他对公司中小股              限制性股票激励计划授予对象朱吉满先生承诺所获股票自授予日起 年 10 36 个
                   朱吉满                                                                                      履行
东所作承诺                    三十六个月内不得转让。                                          月 31 月
                                                                                                               中
                                                                                              日

承诺是否及时履行 是

未完成履行的具体
原因及下一步计划 无
(如有)


四、对 2015 年度经营业绩的预计

2015 年度预计的经营业绩情况:归属于上市公司股东的净利润为正值且不属于扭亏为盈的情形
归属于上市公司股东的净利润为正值且不属于扭亏为盈的情形

2015 年度归属于上市公司股东的净利润变动幅度                                50.00%   至                       70.00%

2015 年度归属于上市公司股东的净利润变动区间(万元)                     66,565.5    至                       75,440.9


                                                    第 10 页
   哈尔滨誉衡药业股份有限公司                                                   2015 年第三季度报告全文

2014 年度归属于上市公司股东的净利润(万元)                                                   44,377.00

                                              1、公司进一步加强市场开发,鹿瓜多肽、注射用头孢米诺钠、
                                              氯吡格雷等基础产品保持了稳定增长,为公司业绩增长奠定了基
                                              础。
                                              2、公司对并购获得的产品安脑丸(片)、葡萄糖酸锌钙口服液、
                                              注射用磷酸肌酸纳进行了协同整合,上述产品实现了快速增长,
                                              已成为支撑公司业绩的重要组成。
业绩变动的原因说明
                                              3、公司继续通过外延并购、合作代理等方式拓宽产品线,银杏
                                              达莫注射液、注射用 12 种复合维生素、注射用黄芪多糖、氯化
                                              钾缓释片、维铁缓释片以及茶碱缓释片、醋酸钙片等品种成为公
                                              司新的盈利增长点。
                                              4、公司生物医药研发费用、新业务管理费用以及利息费用的增
                                              长,对 2015 年的净利润产生较大影响。




                                              第 11 页
   哈尔滨誉衡药业股份有限公司                                                        2015 年第三季度报告全文




                                       第四节 财务报表

一、财务报表
1、合并资产负债表

编制单位:哈尔滨誉衡药业股份有限公司
                                                                                           2015 年 09 月 30 日
                                                                                                     单位:元

                         项目                                 期末余额                  期初余额

流动资产:

    货币资金                                                      981,210,124.37            1,071,153,646.16

    结算备付金

    拆出资金

    以公允价值计量且其变动计入当期损益的金融资产

    衍生金融资产

    应收票据                                                       21,644,680.94               12,303,063.91

    应收账款                                                      113,748,286.61              108,048,800.41

    预付款项                                                      201,580,758.79              114,570,665.13

    应收保费

    应收分保账款

    应收分保合同准备金

    应收利息                                                             15,774.00                 471,828.56

    应收股利

    其他应收款                                                     80,884,257.96               53,634,666.41

    买入返售金融资产

    存货                                                          258,463,970.87              163,445,036.83

    划分为持有待售的资产

    一年内到期的非流动资产                                           6,548,494.34               1,340,962.52

    其他流动资产                                                   33,735,605.25                9,276,704.89

流动资产合计                                                     1,697,831,953.13           1,534,245,374.82

非流动资产:

    发放贷款及垫款

    可供出售金融资产                                               50,832,196.80               11,300,796.80

    持有至到期投资



                                                   第 12 页
   哈尔滨誉衡药业股份有限公司                                                    2015 年第三季度报告全文

    长期应收款

    长期股权投资                                                  3,000,000.00

    投资性房地产

    固定资产                                                  1,491,451,035.04            811,046,254.34

    在建工程                                                   205,756,352.31              20,354,834.70

    工程物资

    固定资产清理

    生产性生物资产                                                  82,450.00

    油气资产

    无形资产                                                   434,184,622.47             370,048,196.70

    开发支出                                                    47,330,014.00              33,504,799.88

    商誉                                                      3,638,786,092.29          1,848,291,450.02

    长期待摊费用                                                  8,269,816.52              6,687,955.39

    递延所得税资产                                              17,129,837.06              12,071,398.83

    其他非流动资产                                             428,721,439.64             274,798,597.08

非流动资产合计                                                6,325,543,856.13          3,388,104,283.74

资产总计                                                      8,023,375,809.26          4,922,349,658.56

流动负债:

    短期借款                                                  1,800,000,000.00            780,000,000.00

    向中央银行借款

    吸收存款及同业存放

    拆入资金

    以公允价值计量且其变动计入当期损益的金融负债

    衍生金融负债

    应付票据                                                   150,095,186.21               9,940,106.00

    应付账款                                                   138,778,982.72              66,950,608.77

    预收款项                                                    79,366,193.08              68,466,499.43

    卖出回购金融资产款

    应付手续费及佣金

    应付职工薪酬                                                  4,889,811.86              4,686,880.57

    应交税费                                                    62,412,063.64              67,390,487.48

    应付利息                                                      2,740,472.23              1,469,808.13

    应付股利                                                      3,189,025.00

    其他应付款                                                 266,167,588.35             269,363,799.10



                                                   第 13 页
   哈尔滨誉衡药业股份有限公司                                 2015 年第三季度报告全文

    应付分保账款

    保险合同准备金

    代理买卖证券款

    代理承销证券款

    划分为持有待售的负债

    一年内到期的非流动负债                 1,229,188,363.17            170,992,020.55

    其他流动负债                             49,000,000.00

流动负债合计                               3,785,827,686.26          1,439,260,210.03

非流动负债:

    长期借款

    应付债券

      其中:优先股

               永续债

    长期应付款                              456,546,984.65             336,702,647.81

    长期应付职工薪酬

    专项应付款                                 2,158,700.49

    预计负债

    递延收益                                 46,287,062.07              15,775,858.38

    递延所得税负债                           34,029,031.35              10,764,610.53

    其他非流动负债                           13,448,500.20              17,656,000.00

非流动负债合计                              552,470,278.76             380,899,116.72

负债合计                                   4,338,297,965.02          1,820,159,326.75

所有者权益:

    股本                                    731,890,250.00             731,890,250.00

    其他权益工具

      其中:优先股

               永续债

    资本公积                               1,270,330,992.22          1,270,330,992.22

    减:库存股

    其他综合收益

    专项储备

    盈余公积                                100,403,545.72             100,403,545.72

    一般风险准备

    未分配利润                             1,344,484,237.63            918,596,455.08



                                第 14 页
   哈尔滨誉衡药业股份有限公司                                                         2015 年第三季度报告全文

归属于母公司所有者权益合计                                       3,447,109,025.57             3,021,221,243.02

    少数股东权益                                                  237,968,818.67                80,969,088.79

所有者权益合计                                                   3,685,077,844.24             3,102,190,331.81

负债和所有者权益总计                                             8,023,375,809.26             4,922,349,658.56


法定代表人:朱吉满                   主管会计工作负责人:刁秀强                       会计机构负责人:程朝阳


2、母公司资产负债表

                                                                                                      单位:元

                       项目                                   期末余额                   期初余额

流动资产:

    货币资金                                                      379,647,149.61               605,448,454.91

    以公允价值计量且其变动计入当期损益的金融资产

    衍生金融资产

    应收票据                                                         4,302,659.30                 2,454,000.00

    应收账款                                                       41,433,888.97                44,752,466.83

    预付款项                                                       30,000,319.49                18,831,189.27

    应收利息                                                                                        255,011.90

    应收股利

    其他应收款                                                    693,939,315.65               777,569,955.97

    存货                                                           33,532,930.36                57,274,243.18

    划分为持有待售的资产

    一年内到期的非流动资产                                               770,996.48                 808,462.52

    其他流动资产                                                   13,030,000.00                    948,760.30

流动资产合计                                                     1,196,657,259.86             1,508,342,544.88

非流动资产:

    可供出售金融资产                                               41,300,796.80                11,300,796.80

    持有至到期投资

    长期应收款

    长期股权投资                                                 4,874,860,475.73             2,225,460,575.73

    投资性房地产

    固定资产                                                      456,531,199.02               477,513,698.94

    在建工程                                                       23,287,522.99                14,343,092.93

    工程物资

    固定资产清理

                                                   第 15 页
   哈尔滨誉衡药业股份有限公司                                                    2015 年第三季度报告全文

    生产性生物资产

    油气资产

    无形资产                                                    71,473,858.39              75,480,773.54

    开发支出                                                    10,656,132.08

    商誉

    长期待摊费用                                                  2,159,186.97              2,670,619.16

    递延所得税资产                                                 795,597.52                795,597.52

    其他非流动资产                                             177,006,097.24             257,082,719.08

非流动资产合计                                                5,658,070,866.74          3,064,647,873.70

资产总计                                                      6,854,728,126.60          4,572,990,418.58

流动负债:

    短期借款                                                  1,150,000,000.00            780,000,000.00

    以公允价值计量且其变动计入当期损益的金融负债

    衍生金融负债

    应付票据                                                                                9,940,106.00

    应付账款                                                    52,382,246.54             113,309,015.27

    预收款项                                                      7,631,865.04             22,669,733.48

    应付职工薪酬                                                   106,621.96                  53,548.66

    应交税费                                                    20,198,884.47              25,246,849.10

    应付利息                                                      1,919,305.56              1,469,808.13

    应付股利                                                      3,189,025.00

    其他应付款                                                 999,127,220.77             571,093,183.06

    划分为持有待售的负债

    一年内到期的非流动负债                                    1,105,634,820.97             84,250,562.75

    其他流动负债

流动负债合计                                                  3,340,189,990.31          1,608,032,806.45

非流动负债:

    长期借款

    应付债券

      其中:优先股

               永续债

    长期应付款                                                 401,399,484.65             158,001,605.61

    长期应付职工薪酬

    专项应付款



                                                   第 16 页
   哈尔滨誉衡药业股份有限公司                                                 2015 年第三季度报告全文

    预计负债

    递延收益                                                  10,749,583.36             11,834,833.35

    递延所得税负债

    其他非流动负债

非流动负债合计                                               412,149,068.01            169,836,438.96

负债合计                                                   3,752,339,058.32           1,777,869,245.41

所有者权益:

    股本                                                     731,890,250.00            731,890,250.00

    其他权益工具

      其中:优先股

               永续债

    资本公积                                               1,395,332,464.90           1,395,332,464.90

    减:库存股

    其他综合收益

    专项储备

    盈余公积                                                 100,403,545.72            100,403,545.72

    未分配利润                                               874,762,807.66            567,494,912.55

所有者权益合计                                             3,102,389,068.28           2,795,121,173.17

负债和所有者权益总计                                       6,854,728,126.60           4,572,990,418.58


法定代表人:朱吉满              主管会计工作负责人:刁秀强                    会计机构负责人:程朝阳


3、合并本报告期利润表

                                                                                              单位:元

                        项目                           本期发生额               上期发生额

一、营业总收入                                               662,947,486.01            465,251,948.32

    其中:营业收入                                           662,947,486.01            465,251,948.32

           利息收入

           已赚保费

           手续费及佣金收入

二、营业总成本                                               467,061,704.28            366,363,488.64

    其中:营业成本                                           241,269,147.66            166,818,632.37

           利息支出

           手续费及佣金支出

           退保金

                                            第 17 页
     哈尔滨誉衡药业股份有限公司                                                   2015 年第三季度报告全文

           赔付支出净额

           提取保险合同准备金净额

           保单红利支出

           分保费用

           营业税金及附加                                          8,299,595.31              4,496,832.35

           销售费用                                               85,564,145.94            100,524,336.41

           管理费用                                              108,073,243.31             86,673,797.30

           财务费用                                               23,025,997.47              8,021,272.75

           资产减值损失                                             829,574.59                -171,382.54

     加:公允价值变动收益(损失以“-”号填列)

         投资收益(损失以“-”号填列)                            1,715,831.58              1,560,602.12

         其中:对联营企业和合营企业的投资收益

         汇兑收益(损失以“-”号填列)

三、营业利润(亏损以“-”号填列)                               197,601,613.31            100,449,061.80

     加:营业外收入                                               17,780,599.38             19,305,527.80

         其中:非流动资产处置利得                                     16,631.82               304,637.40

     减:营业外支出                                                 262,029.32                200,464.95

         其中:非流动资产处置损失                                    -38,762.28               206,030.39

四、利润总额(亏损总额以“-”号填列)                           215,120,183.37            119,554,124.65

     减:所得税费用                                               31,468,033.06             19,769,078.04

五、净利润(净亏损以“-”号填列)                               183,652,150.31             99,785,046.61

     归属于母公司所有者的净利润                                  175,382,136.73             95,517,370.90

     少数股东损益                                                  8,270,013.58              4,267,675.71

六、其他综合收益的税后净额

  归属母公司所有者的其他综合收益的税后净额

     (一)以后不能重分类进损益的其他综合收益

           1.重新计量设定受益计划净负债或净资产的变


           2.权益法下在被投资单位不能重分类进损益的
其他综合收益中享有的份额

     (二)以后将重分类进损益的其他综合收益

           1.权益法下在被投资单位以后将重分类进损益
的其他综合收益中享有的份额

           2.可供出售金融资产公允价值变动损益

           3.持有至到期投资重分类为可供出售金融资产


                                                      第 18 页
   哈尔滨誉衡药业股份有限公司                                                           2015 年第三季度报告全文

损益

          4.现金流量套期损益的有效部分

          5.外币财务报表折算差额

          6.其他

  归属于少数股东的其他综合收益的税后净额

七、综合收益总额                                                      183,652,150.31              99,785,046.61

    归属于母公司所有者的综合收益总额                                  175,382,136.73              95,517,370.90

    归属于少数股东的综合收益总额                                        8,270,013.58               4,267,675.71

八、每股收益:

    (一)基本每股收益                                                           0.24                        0.14

    (二)稀释每股收益                                                           0.24                        0.14

本期发生同一控制下企业合并的,被合并方在合并前实现的净利润为:0.00 元,上期被合并方实现的净利润为:0.00 元。


法定代表人:朱吉满                       主管会计工作负责人:刁秀强                     会计机构负责人:程朝阳


4、母公司本报告期利润表

                                                                                                         单位:元

                         项目                                   本期发生额                上期发生额

一、营业收入                                                          170,543,503.29             133,047,749.20

    减:营业成本                                                       49,255,497.81              46,327,973.64

        营业税金及附加                                                  2,864,034.75               2,119,611.85

        销售费用                                                       46,170,452.19              32,359,804.50

        管理费用                                                       51,742,219.92              56,758,837.01

        财务费用                                                       15,973,750.27               8,518,975.01

        资产减值损失                                                     767,464.16                 -151,219.88

    加:公允价值变动收益(损失以“-”号填列)

        投资收益(损失以“-”号填列)                                 93,648,671.40             112,790,216.98

        其中:对联营企业和合营企业的投资收益

二、营业利润(亏损以“-”号填列)                                     97,418,755.59              99,903,984.05

    加:营业外收入                                                      8,870,245.38                   836,992.68

        其中:非流动资产处置利得                                         383,761.82                    273,300.00

    减:营业外支出                                                           1,537.00                  178,627.83

        其中:非流动资产处置损失                                                 0.00                  173,627.83

三、利润总额(亏损总额以“-”号填列)                                106,287,463.97             100,562,348.90

    减:所得税费用                                                      1,409,658.44              -1,858,899.20


                                                     第 19 页
     哈尔滨誉衡药业股份有限公司                                                         2015 年第三季度报告全文

四、净利润(净亏损以“-”号填列)                                     104,877,805.53            102,421,248.10

五、其他综合收益的税后净额

     (一)以后不能重分类进损益的其他综合收益

           1.重新计量设定受益计划净负债或净资产的变


           2.权益法下在被投资单位不能重分类进损益的
其他综合收益中享有的份额

     (二)以后将重分类进损益的其他综合收益

           1.权益法下在被投资单位以后将重分类进损益
的其他综合收益中享有的份额

           2.可供出售金融资产公允价值变动损益

           3.持有至到期投资重分类为可供出售金融资产
损益

           4.现金流量套期损益的有效部分

           5.外币财务报表折算差额

           6.其他

六、综合收益总额                                                       104,877,805.53            102,421,248.10

七、每股收益:

     (一)基本每股收益                                                          0.14                       0.15

     (二)稀释每股收益                                                          0.14                       0.15


法定代表人:朱吉满                        主管会计工作负责人:刁秀强                    会计机构负责人:程朝阳


5、合并年初到报告期末利润表

                                                                                                        单位:元

                          项目                                   本期发生额               上期发生额

一、营业总收入                                                       1,927,552,868.07           1,371,851,676.94

     其中:营业收入                                                  1,927,552,868.07           1,371,851,676.94

           利息收入

           已赚保费

           手续费及佣金收入

二、营业总成本                                                       1,337,580,876.55           1,040,695,638.96

     其中:营业成本                                                    699,588,980.68            515,173,340.16

           利息支出

           手续费及佣金支出



                                                      第 20 页
     哈尔滨誉衡药业股份有限公司                                                   2015 年第三季度报告全文

           退保金

           赔付支出净额

           提取保险合同准备金净额

           保单红利支出

           分保费用

           营业税金及附加                                         25,951,004.42             17,740,197.85

           销售费用                                              258,382,631.54            311,850,965.14

           管理费用                                              292,604,197.69            178,611,331.10

           财务费用                                               60,156,286.25             16,803,880.99

           资产减值损失                                             897,775.97                515,923.72

     加:公允价值变动收益(损失以“-”号填列)

         投资收益(损失以“-”号填列)                            4,313,175.54              5,002,496.60

         其中:对联营企业和合营企业的投资收益

         汇兑收益(损失以“-”号填列)

三、营业利润(亏损以“-”号填列)                               594,285,167.06            336,158,534.58

     加:营业外收入                                               31,529,278.16             36,465,516.66

         其中:非流动资产处置利得                                   520,678.35                304,637.40

     减:营业外支出                                                 424,565.39               3,816,309.72

         其中:非流动资产处置损失                                     70,765.26               223,022.52

四、利润总额(亏损总额以“-”号填列)                           625,389,879.83            368,807,741.52

     减:所得税费用                                              101,075,260.71             62,399,942.09

五、净利润(净亏损以“-”号填列)                               524,314,619.12            306,407,799.43

     归属于母公司所有者的净利润                                  499,076,807.55            298,182,749.42

     少数股东损益                                                 25,237,811.57              8,225,050.01

六、其他综合收益的税后净额

  归属母公司所有者的其他综合收益的税后净额

     (一)以后不能重分类进损益的其他综合收益

           1.重新计量设定受益计划净负债或净资产的变


           2.权益法下在被投资单位不能重分类进损益的
其他综合收益中享有的份额

     (二)以后将重分类进损益的其他综合收益

           1.权益法下在被投资单位以后将重分类进损益
的其他综合收益中享有的份额

           2.可供出售金融资产公允价值变动损益


                                                      第 21 页
   哈尔滨誉衡药业股份有限公司                                                            2015 年第三季度报告全文

          3.持有至到期投资重分类为可供出售金融资产
损益

          4.现金流量套期损益的有效部分

          5.外币财务报表折算差额

          6.其他

  归属于少数股东的其他综合收益的税后净额

七、综合收益总额                                                      524,314,619.12              306,407,799.43

    归属于母公司所有者的综合收益总额                                  499,076,807.55              298,182,749.42

    归属于少数股东的综合收益总额                                       25,237,811.57                8,225,050.01

八、每股收益:

    (一)基本每股收益                                                            0.68                        0.43

    (二)稀释每股收益                                                            0.68                        0.43

本期发生同一控制下企业合并的,被合并方在合并前实现的净利润为:0.00 元,上期被合并方实现的净利润为:0.00 元。


法定代表人:朱吉满                       主管会计工作负责人:刁秀强                      会计机构负责人:程朝阳


6、母公司年初到报告期末利润表

                                                                                                          单位:元

                         项目                                   本期发生额                 上期发生额

一、营业收入                                                          446,941,285.80              396,316,022.56

    减:营业成本                                                      130,895,597.54              126,428,213.64

        营业税金及附加                                                  7,521,358.25                6,185,219.18

        销售费用                                                      120,156,148.82              104,363,240.65

        管理费用                                                      126,711,578.76              105,030,866.53

        财务费用                                                       44,840,298.44               18,458,692.39

        资产减值损失                                                     997,561.08                     402,030.28

    加:公允价值变动收益(损失以“-”号填列)

        投资收益(损失以“-”号填列)                                360,144,846.01              114,544,960.62

        其中:对联营企业和合营企业的投资收益

二、营业利润(亏损以“-”号填列)                                    375,963,588.92              149,992,720.51

    加:营业外收入                                                     11,974,396.47                2,104,725.80

        其中:非流动资产处置利得                                         383,761.82                     273,300.00

    减:营业外支出                                                           25,907.77              3,389,279.72

        其中:非流动资产处置损失                                              9,162.62                  173,627.83

三、利润总额(亏损总额以“-”号填列)                                387,912,077.62              148,708,166.59


                                                     第 22 页
     哈尔滨誉衡药业股份有限公司                                                         2015 年第三季度报告全文

     减:所得税费用                                                      7,455,157.51               7,481,406.20

四、净利润(净亏损以“-”号填列)                                     380,456,920.11            141,226,760.39

五、其他综合收益的税后净额

     (一)以后不能重分类进损益的其他综合收益

           1.重新计量设定受益计划净负债或净资产的变


           2.权益法下在被投资单位不能重分类进损益的
其他综合收益中享有的份额

     (二)以后将重分类进损益的其他综合收益

           1.权益法下在被投资单位以后将重分类进损益
的其他综合收益中享有的份额

           2.可供出售金融资产公允价值变动损益

           3.持有至到期投资重分类为可供出售金融资产
损益

           4.现金流量套期损益的有效部分

           5.外币财务报表折算差额

           6.其他

六、综合收益总额                                                       380,456,920.11            141,226,760.39

七、每股收益:

     (一)基本每股收益                                                          0.52                       0.20

     (二)稀释每股收益                                                          0.52                       0.20


法定代表人:朱吉满                        主管会计工作负责人:刁秀强                    会计机构负责人:程朝阳


7、合并年初到报告期末现金流量表

                                                                                                        单位:元

                          项目                                   本期发生额               上期发生额

一、经营活动产生的现金流量:

     销售商品、提供劳务收到的现金                                    2,209,199,302.30           1,704,878,983.81

     客户存款和同业存放款项净增加额

     向中央银行借款净增加额

     向其他金融机构拆入资金净增加额

     收到原保险合同保费取得的现金

     收到再保险业务现金净额

     保户储金及投资款净增加额



                                                      第 23 页
   哈尔滨誉衡药业股份有限公司                                                     2015 年第三季度报告全文

    处置以公允价值计量且其变动计入当期损益的金融
资产净增加额

    收取利息、手续费及佣金的现金

    拆入资金净增加额

    回购业务资金净增加额

    收到的税费返还

    收到其他与经营活动有关的现金                                671,041,568.76             279,636,955.56

经营活动现金流入小计                                          2,880,240,871.06           1,984,515,939.37

    购买商品、接受劳务支付的现金                                824,064,193.44             641,057,632.15

    客户贷款及垫款净增加额

    存放中央银行和同业款项净增加额

    支付原保险合同赔付款项的现金

    支付利息、手续费及佣金的现金

    支付保单红利的现金

    支付给职工以及为职工支付的现金                              188,515,024.90              89,494,532.86

    支付的各项税费                                              377,586,272.36             254,904,997.18

    支付其他与经营活动有关的现金                                890,051,130.82             647,137,828.35

经营活动现金流出小计                                          2,280,216,621.52           1,632,594,990.54

经营活动产生的现金流量净额                                      600,024,249.54             351,920,948.83

二、投资活动产生的现金流量:

    收回投资收到的现金                                        3,494,094,767.12           1,584,403,800.00

    取得投资收益收到的现金                                        4,308,408.42               5,002,496.60

    处置固定资产、无形资产和其他长期资产收回的现金
                                                                    703,939.00                621,316.91
净额

    处置子公司及其他营业单位收到的现金净额

    收到其他与投资活动有关的现金

投资活动现金流入小计                                          3,499,107,114.54           1,590,027,613.51

    购建固定资产、无形资产和其他长期资产支付的现金              174,671,107.54              92,618,873.65

    投资支付的现金                                            3,519,651,400.00           1,493,668,281.10

    质押贷款净增加额

    取得子公司及其他营业单位支付的现金净额                    1,128,352,424.26           1,261,673,551.38

    支付其他与投资活动有关的现金                                295,840,000.00                       0.00

投资活动现金流出小计                                          5,118,514,931.80           2,847,960,706.13

投资活动产生的现金流量净额                                    -1,619,407,817.26         -1,257,933,092.62

三、筹资活动产生的现金流量:


                                                   第 24 页
   哈尔滨誉衡药业股份有限公司                                                        2015 年第三季度报告全文

    吸收投资收到的现金

    其中:子公司吸收少数股东投资收到的现金

    取得借款收到的现金                                            2,000,000,000.00            630,000,000.00

    发行债券收到的现金

    收到其他与筹资活动有关的现金                                     49,000,000.00               1,137,424.15

筹资活动现金流入小计                                              2,049,000,000.00            631,137,424.15

    偿还债务支付的现金                                              980,000,000.00            150,000,000.00

    分配股利、利润或偿付利息支付的现金                              139,444,916.56             55,996,281.79

    其中:子公司支付给少数股东的股利、利润                           10,648,500.00

    支付其他与筹资活动有关的现金                                     68,815,201.14                    716.37

筹资活动现金流出小计                                              1,188,260,117.70            205,996,998.16

筹资活动产生的现金流量净额                                          860,739,882.30            425,140,425.99

四、汇率变动对现金及现金等价物的影响                                          1.96                     49.26

五、现金及现金等价物净增加额                                      -158,643,683.46            -480,871,668.54

    加:期初现金及现金等价物余额                                  1,071,101,367.31            829,922,662.07

六、期末现金及现金等价物余额                                        912,457,683.85            349,050,993.53


法定代表人:朱吉满                     主管会计工作负责人:刁秀强                    会计机构负责人:程朝阳


8、母公司年初到报告期末现金流量表

                                                                                                     单位:元

                         项目                                 本期发生额               上期发生额

一、经营活动产生的现金流量:

    销售商品、提供劳务收到的现金                                    481,969,855.12            514,052,868.48

    收到的税费返还

    收到其他与经营活动有关的现金                                  2,520,230,983.09           1,227,512,214.16

经营活动现金流入小计                                              3,002,200,838.21           1,741,565,082.64

    购买商品、接受劳务支付的现金                                    158,290,109.40            181,326,897.89

    支付给职工以及为职工支付的现金                                   54,300,241.98             28,390,922.24

    支付的各项税费                                                   82,422,425.90             85,356,567.09

    支付其他与经营活动有关的现金                                  2,153,841,580.60           1,658,458,177.81

经营活动现金流出小计                                              2,448,854,357.88           1,953,532,565.03

经营活动产生的现金流量净额                                          553,346,480.33            -211,967,482.39

二、投资活动产生的现金流量:

    收回投资收到的现金                                            2,951,040,000.00           1,158,003,800.00

                                                   第 25 页
   哈尔滨誉衡药业股份有限公司                                                           2015 年第三季度报告全文

    取得投资收益收到的现金                                          362,119,983.70                 2,601,542.29

    处置固定资产、无形资产和其他长期资产收回的现金
                                                                       497,900.00                   309,800.00
净额

    处置子公司及其他营业单位收到的现金净额

    收到其他与投资活动有关的现金

投资活动现金流入小计                                           3,313,657,883.70                1,160,915,142.29

    购建固定资产、无形资产和其他长期资产支付的现金                   73,774,259.40                50,888,548.26

    投资支付的现金                                             2,967,070,000.00                  961,284,531.10

    取得子公司及其他营业单位支付的现金净额                     1,213,617,762.74                  842,432,237.91

    支付其他与投资活动有关的现金                                     95,840,000.00                         0.00

投资活动现金流出小计                                           4,350,302,022.14                1,854,605,317.27

投资活动产生的现金流量净额                                     -1,036,644,138.44                -693,690,174.98

三、筹资活动产生的现金流量:

    吸收投资收到的现金

    取得借款收到的现金                                         1,350,000,000.00                  630,000,000.00

    发行债券收到的现金

    收到其他与筹资活动有关的现金                                                                   1,093,476.04

筹资活动现金流入小计                                           1,350,000,000.00                  631,093,476.04

    偿还债务支付的现金                                              980,000,000.00               150,000,000.00

    分配股利、利润或偿付利息支付的现金                              112,462,166.57                49,217,971.25

    支付其他与筹资活动有关的现金                                         66,342.93                      716.37

筹资活动现金流出小计                                           1,092,528,509.50                  199,218,687.62

筹资活动产生的现金流量净额                                          257,471,490.50               431,874,788.42

四、汇率变动对现金及现金等价物的影响                                                                     48.94

五、现金及现金等价物净增加额                                    -225,826,167.61                 -473,782,820.01

    加:期初现金及现金等价物余额                                    605,448,454.91               635,712,358.06

六、期末现金及现金等价物余额                                        379,622,287.30               161,929,538.05


法定代表人:朱吉满                     主管会计工作负责人:刁秀强                      会计机构负责人:程朝阳




                                                                                     哈尔滨誉衡药业股份有限公司

                                                                                             法定代表人:朱吉满

                                                                                         二〇一五年十月二十七日




                                                   第 26 页